CD274 and head and neck squamous cell carcinoma: A study into the use of TILT-123 and avelumab for treating melanoma and HNSCC after anti-PD-L1 therapy (AVENTIL) (NCT05222932) has been designed and is currently recruiting patients (Good Clinical Practice Network, 2025).